This review presents an updated meta-analysis of trials reaffirming the cardiorenal risk-reducing benefits of SGLT2 inhibitors in patients with T2D, CKD, and HF, and of incretin-based therapies in those with T2D and CKD. This evidence concerns the gene SLC5A2 and chronic kidney disease.